Regeneron Pharmaceuticals has announced a monumental research collaboration with Parabilis Medicines, a deal valued at an impressive $2.32 billion. This…
Read More
UK Secures Favipiravir Supply from Japan to Bolster Hantavirus Preparedness
The United Kingdom has received a crucial supply of the antiviral medication favipiravir from the Japanese government, a strategic move…
Read More
VERTANICAL’s Investigational Non-Opioid Chronic Low Back Pain Treatment VER-01 Receives FDA Breakthrough Therapy Designation
VERTANICAL has announced a significant milestone in its development of VER-01, an investigational non-opioid therapeutic candidate for chronic low back…
Read More
Japan Approves Jascayd (nerandomilast) for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Boehringer Ingelheim has achieved a significant milestone in the treatment of interstitial lung diseases with the approval of Jascayd (nerandomilast)…
Read More
FDA Leadership Turmoil Intensifies as Key Officials Ousted Amidst Political Maneuvering
The leadership landscape within the U.S. Department of Health and Human Services (HHS) is undergoing a significant and turbulent transformation,…
Read More
WHO Declares Ebola Outbreak a Public Health Emergency of International Concern Amidst Unprecedented Challenges
The World Health Organization (WHO) has officially declared the current Ebola disease outbreak in Sub-Saharan Africa a public health emergency…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025.
The pharmaceutical industry witnessed a significant shift in its commercial landscape during Fiscal Year 2025, with Merck’s oncology powerhouse, Keytruda…
Read More
Pharma 50: The 50 best-selling drugs of FY2025
The fiscal year 2025 concluded with a dramatic reshuffling at the pinnacle of the pharmaceutical industry’s sales leaderboard, signaling profound…
Read More
Tirzepatide Confirmed as Best-in-Class Obesity Therapy Following Landmark SURMOUNT-MAINTAIN Trial Results
Findings from the pivotal Phase III SURMOUNT-MAINTAIN trial, presented at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye,…
Read More
Kyowa Kirin Secures FDA Approval for Enhanced Crysvita Dosing Regimen for Adults with X-Linked Hypophosphatemia
Kyowa Kirin has announced a significant advancement in the treatment landscape for X-linked hypophosphatemia (XLH) in adult patients, following the…
Read MoreYOU MAY HAVE MISSED
